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Background:  A subset  of  patients  with  hypertrophic  cardiomyopathy  (HCM)  has  been  reported  to
progress  into  dilated-HCM  (D-HCM),  characterized  by left  ventricular  (LV)  systolic  dysfunction  and  cav-
ity dilatation,  resembling  idiopathic  dilated  cardiomyopathy  (DCM).  We  compared  the  characteristics,
treatments,  and  outcomes  in patients  with  heart  failure  (HF)  due  to D-HCM  vs.  DCM  by  using  national
registry  data  in Japan.
Methods  and  results:  The  Japanese  Cardiac  Registry  of  Heart  Failure  in  Cardiology  (JCARE-CARD)  is a
prospective  observational  study  of  patients  hospitalized  due  to worsening  HF  with  an  average  of  2.2
years  of follow-up.  Patients  with  D-HCM  (n = 41)  were  more  likely  to be  male,  have  prior  stroke,  atrial
ﬁbrillation,  and sustained  ventricular  tachycardia  or ventricular  ﬁbrillation  compared  with  DCM  (n =  486).
Echocardiography  demonstrated  that  D-HCM  patients  had  smaller  LV end-systolic  diameter,  higher  ejec-
tion fraction,  and  greater  wall thickness.  Treatments  for HF including  angiotensin-converting  enzyme
inhibitor  or  angiotensin  receptor  blocker,  -blocker,  and  spironolactone  were  similar  between  groups
except  for  higher  use  of  amiodarone,  warfarin,  and  implantable  cardioverter-deﬁbrillator  for D-HCM.
Mortality  was  signiﬁcantly  higher  in patients  with  D-HCM  (29.7%  vs. 14.4%;  p  < 0.05).  Sudden  death  tended
to  be higher  also  in  D-HCM  (8.1%  vs. 2.6%;  p =  0.06),  which,  however,  did  not  reach  statistical  signiﬁcance.
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A subset of patients with hypertrophic cardiomyopathy (HCM)
as been reported to progress into the dilated and/or end-stage
hase, the so-called dilated phase of HCM (D-HCM), characterized
y left ventricular (LV) systolic dysfunction and cavity dilatation.
-HCM has been recognized as a not rare complication with distinc-
ively unique clinical features [1–12]. One such feature of D-HCM
s unfavorable outcomes including higher risk of sudden cardiac
eath. Therefore, it is of critical importance to analyze the clin-
cal characteristics, treatment strategies, and prognosis for these
atients in a large, multicenter population. Harris et al. reported
hat, using the data of 44 patients with the end-stage phase of
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niversity Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-
638, Japan. Tel.: +81 11 706 6970; fax: +81 11 706 7874.
E-mail addresses: cvsecret@med.hokudai.ac.jp,
tsutsui@med.hokudai.ac.jp (H. Tsutsui).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.08.010-HCM  had  higher  mortality  risk  than  those  with  DCM.  Effective  manage-
eeded  to  be established  for D-HCM.
anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
HCM obtained from 3 HCM cohorts composed of 1259 patients,
D-HCM patients had more atrial ﬁbrillation, impaired LV function
that precedes cavity dilatation, wall thinning, and heart failure
(HF) symptoms [11]. Strikingly, their prognosis was  unfavorable
with a mortality rate as high as 11% per year. A recent study by
Hamada et al. also demonstrated that patients with D-HCM were
more symptomatic at diagnosis and their prognosis was worse than
that for patients with idiopathic dilated cardiomyopathy (DCM)
[12]. Even though their study provided a valuable insight into the
characteristics of D-HCM patients in Japan, they were data from a
single center of a university hospital. Therefore, we need to analyze
the data for D-HCM patients obtained from multiple hospitals on a
national basis.
The Japanese Cardiac Registry of Heart Failure in Cardiology
(JCARE-CARD) is a national prospective registry database describ-
ing the clinical characteristics, treatments, and long-term outcomes
of patients hospitalized due to the worsening of HF symptoms
[13–18]. It included HF patients with D-HCM as well as DCM and
thus could enable us to compare these 2 groups of patients.
vier Ltd. All rights reserved.
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ethods
aseline patient data
The details of the JCARE-CARD were described previously
13,14]. Brieﬂy, eligible patients were those hospitalized due to
orsening HF as the primary cause of admission. Baseline data
ere collected by using an electronic data capture system, which
ncluded demography, causes of HF, medical history, clinical status,
chocardiography, plasma brain-type natriuretic peptide (BNP),
nd treatments including medications at discharge.
Diagnosis of HCM was based on echocardiographic documen-
ation of a hypertrophied nondilated LV in the absence of another
ardiac or systemic disease that could produce the magnitude of
ypertrophy evident at some time during the natural course of the
isease [19]. D-HCM was deﬁned as an LV ejection fraction (EF)
50% at rest, reﬂecting global systolic dysfunction, at study entry
r during follow-up, by 2 dimensional echocardiography.
DCM was diagnosed by a dilated LV (end-diastolic diameter
55 mm)  and reduced EF <50% in the absence of any speciﬁc cardiac
r systemic diseases such as coronary artery disease, valvular heart
isease, storage disease, and history of cardiotoxic drug use.
utcomesThe status of registered patients was surveyed during hospital-
zation and at least 1 year after discharge and the following infor-
ation was obtained: death, causes of death, and rehospitalization
able 1
aseline characteristics of HF patients with D-HCM vs. DCM.
Characteristics Total (n = 527) 
Age, yrs (mean ± SD) 63.5 ± 13.9 
Male,  % 73.1 
BMI,  kg/m2 22.6 ± 4.1 
Duration of HF, months (mean ± SD) 47.5 ± 63.2 
Medical history, %
Hypertension 31.7 
Diabetes mellitus 23.9 
Dyslipidemia 20.8 
Hyperuricemia 48.3 
COPD  6.0 
Smoking 43.7 
Prior  stroke 10.3 
Prior  myocardial infarction 3.3 
Atrial  ﬁbrillation 33.7 
Sustained VT/VF 8.5 
Vital  signs at discharge
NYHA functional class, %
1 32.7 
2  57 
3  7.5 
4  2.9 
Heart  rate, bpm 71.1 ± 12.3 
SBP,  mmHg  110.2 ± 17.2 
DBP,  mmHg 65.2 ± 11.4 
Laboratory data at discharge
eGFR, mL/min/1.73 m2 56.6 ± 23.7 
Serum uric acid (mg/dL) 7.4 ± 2.3 
Hemoglobin, g/dL 13.2 ± 2.2 
Plasma BNP, pg/mL 370 ± 438 
Echocardiographic data
LV EDD, mm 64.0 ± 8.5 
LV  ESD, mm 64.0 ± 8.5 
LVEF,  % 29.4 ± 11.2 
IVST,  mm 9.6 ± 2.3 
LV  PWT, mm  9.6 ± 2.0 
Severe mitral regurgitation, % 30.6 
-HCM, dilated phase hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; BMI
T/VF,  ventricular tachycardia/ﬁbrillation; NYHA, New York Heart Association; SBP, sy
ltration rate; BNP, B-type natriuretic peptide; LV, left ventricular; EDD, end-diastolic 
eptal thickness; PWT; posterior wall thickness. Data are shown as percent or means ± SDiology 61 (2013) 65–70
due to the exacerbation of HF that required more than continua-
tion of their usual therapy on prior admission. Out of 527 registered
patients, the follow-up data could be obtained in 455 patients
(86.3%; 37 and 418 for D-HCM and DCM, respectively). Mean post-
discharge follow-up was  815 ± 299 days (2.2 ± 0.8 years).
Statistical analysis
Patient characteristics and treatments were compared using
Pearson 2 test for categorical variables, Student t-test for nor-
mally distributed continuous variables, and Mann–Whitney U test
for continuous variables not normally distributed. Kaplan–Meier
method was applied to all cause-death, cardiac death, sudden
death, and rehospitalization due to worsening HF after discharge.
A Cox proportional hazard model was  used in the analysis adjusted
for the following covariates: age, sex, diabetes mellitus, prior
stroke, atrial ﬁbrillation, sustained ventricular tachycardia and/or
ﬁbrillation, heart rate, diastolic blood pressure, LVEF, wall thickness
of interventricular septum and posterior wall. SPSS version 16.0 J
was used for all statistical analyses, and p < 0.05 was considered
signiﬁcant.
ResultsPatient characteristics
Table 1 compares the baseline clinical characteristics among
patients with D-HCM (n = 41) and DCM (n = 486). Compared with
D-HCM (n = 41) DCM (n = 486) p-Value
63.6 ± 14.3 63.5 ± 13.8 0.963
87.8 71.8 0.027
23.3 ± 3.2 22.5 ± 4.2 0.132
39.5 ± 32.6 48.1 ± 65.0 0.236
24.4 32.4 0.292
0.0 25.9 <0.001
26.8 20.2 0.318
62.5 47.2 0.062
2.5 6.3 0.330
33.3 44.4 0.214
23.7 9.3 0.005
7.3 2.9 0.128
51.2 32.2 0.014
23.1 7.3 0.001
26.8 33.2 0.844
63.4 56.4
7.3 7.5
2.4 2.9
66.0 ± 10.6 71.5 ± 12.4 0.015
105.0 ± 23.2 110.6 ± 16.6 0.14
60.3 ± 13.7 65.6 ± 11.1 0.007
53.1 ± 25.9 56.9 ± 23.5 0.121
7.8 ± 2.4 7.4 ± 2.3 0.318
13.7 ± 1.9 13.1 ± 2.2 0.203
450 ± 391 365 ± 411 0.154
60.3 ± 13.7 65.6 ± 11.1 0.127
50.3 ± 7.9 55.0 ± 9.4 0.003
34.4 ± 11.5 29.0 ± 11.0 0.005
11.7 ± 3.6 9.4 ± 2.1 <0.001
10.8 ± 2.9 9.5 ± 1.9 0.004
26.5 30.9 0.586
, body mass index; HF, heart failure; COPD, chronic obstructive pulmonary disease;
stolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular
diameter; ESD, end-systolic diameter; EF, ejection fraction; IVST, interventricular
.
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atients with DCM, the patients with D-HCM were more male and
ore likely to have a history of stroke, atrial ﬁbrillation, and sus-
ained ventricular tachycardia and/or ﬁbrillation.
New York Heart Association functional class at discharge was
omparable between groups. Plasma BNP levels were elevated in
oth D-HCM and DCM patients, but they did not differ between
roups (450 ± 391 pg/mL vs. 365 ± 411 pg/mL; p = 0.154). Echocar-
iographic data showed that LV cavity diameters were increased
nd EF was decreased in both groups. However, compared to
CM, LV end-systolic diameter was smaller (50.3 ± 7.9 mm vs.
5.0 ± 9.4 mm;  p = 0.003) and EF was greater (34.4 ± 11.5% vs.
9.0 ± 11.0%; p = 0.005) in patients with D-HCM. As expected, the
all thickness of interventricular septum and posterior wall was
reater in D-HCM than in DCM. The prevalence of severe mitral
egurgitation was comparable between groups.
reatments
Table 2 compares the medication and procedure use at the
ime of discharge. The majority of both D-HCM and DCM patients
ere treated with angiotensin-converting enzyme (ACE) inhibitors
r angiotensin receptor blockers (ARBs; 80–90%) and -blocker
approximately 73%), which did not differ between groups. The
se of spironolactone was also comparable between groups (42.5%
s. 46.9%, p = 0.592). In contrast, the use of antiarrhythmics includ-
ng amiodarone was signiﬁcantly higher in patients with D-HCM
30.0% vs. 15.4%, p = 0.017). Implantable cardioverter-deﬁbrillator
ICD) use was also higher in D-HCM compared to DCM (20.0% vs.
.8%, p < 0.001). The use of warfarin was higher in D-HCM compared
o DCM (77.5% vs. 49.9%, p = 0.001).
ong-term outcomes
During the follow-up period, 29.7% of D-HCM patients died,
hich was signiﬁcantly higher than the 14.4% for DCM patientsp < 0.05) (Fig. 1). The rate of cardiac death (21.6% vs. 9.8%; p = 0.08)
nd sudden death (8.1% vs. 2.6%; p = 0.06) tended to be higher in
-HCM than DCM, which, however, did not reach statistical signif-
cance. The rate of rehospitalization during the same period tended
able 2
ischarge medications and procedures for HF Patients with D-HCM vs. DCM.
Total (n = 527) D
Medications, %
ACE inhibitor 48.9 4
ARB  47.0 4
ACE  inhibitor or ARB 88.4 8
ACE  inhibitor and ARB 7.5 
-Blocker 73.9 7
Diuretics 90.0 9
Loop  diuretics 79.2 8
Spironolactone 46.6 4
Digitalis 39.1 3
Ca  channel blocker 11.8 1
Nitrates 11.4 1
Antiarrhythmics 26.1 4
Amiodarone 16.5 3
Aspirin 28.3 2
Warfarin 52.1 7
Statin  14.3 1
Procedures, %
PCI 5.1 
Valvular surgery 1.0 
PPM  0.8 
ICD  4.1 2
CRT  4.7 
-HCM, dilated hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; ACE, angi
oronary intervention; PPM, permanent pacemaker; ICD, implantable cardioverter deﬁbriology 61 (2013) 65–70 67
to be higher in patients with D-HCM than DCM, which was not
statistically signiﬁcant (43.2% vs. 31.8%, p = 0.102).
After adjustment for covariates in multivariate Cox proportional
hazard models, patients with D-HCM were not signiﬁcantly asso-
ciated with higher risk of all-cause death [hazard ratio (HR) 1.832,
95% conﬁdence interval (CI) 0.775–4.329, p = 0.168], cardiac death
(HR 2.219, 95% CI 0.726–6.777, p = 0.162), sudden death (HR 0.725,
95% CI 0.058–9.098, p = 0.803), and rehospitalization due to wors-
ening HF (HR 1.174, 95% CI 0.578–2.385, p = 0.657) compared to
those with DCM (Table 3).
Deletion of 3 D-HCM patients and 14 DCM patients with prior
myocardial infarction did not affect the overall results. The rate of
all-cause death in D-HCM patients without prior myocardial infarc-
tion was  signiﬁcantly higher than that for DCM patients (HR 2.128,
95% CI 1.088–4.165, p = 0.024). The rate of cardiac death (HR 2.14,
95% CI 0.959–4.776, p = 0.057) and sudden death (HR 3.393, 95% CI
0.946–12.166, p = 0.046) tended to be higher in D-HCM than DCM
without prior myocardial infarction, which, however, did not reach
statistical signiﬁcance. They did not signiﬁcantly differ between
groups after adjustment for covariates in multivariate Cox propor-
tional hazard models.
Discussion
The present study based on the JCARE-CARD provides a com-
parison of the clinical characteristics, treatments, and outcomes
of HF patients due to D-HCM vs. DCM in routine clinical practice
in Japan. It conﬁrmed previous studies that D-HCM patients had
more atrial ﬁbrillation, sustained ventricular tachycardia and/or
ﬁbrillation, and poor prognosis [11,12].
The number of D-HCM (n = 41) was  smaller than those of DCM
(n = 486) in this study. Prevalence of HCM is about 0.2% in general
population and about 3% of HCM patients manifest the end stage
characterized by systolic dysfunction (LVEF <50%) [11,20]. Conse-
quently, the prevalence of D-HCM was  estimated as 0.006%. On the
other hand, the prevalence of DCM has been reported to be approx-
imately 0.036% in the general population [21]. The ratio of D-HCM
to DCM is estimated to be 1–6 in the general population. The ratio
in this study (1–12) might be lower than the estimated value in
general population, which might be due to the selection bias of the
-HCM (n = 41) DCM (n = 486) p-Value
2.5 49.5 0.397
5.0 47.1 0.796
0.0 89.1 0.084
7.5 7.5 0.993
2.5 74.0 0.837
7.5 89.3 0.099
0.0 79.1 0.893
2.5 46.9 0.592
5.0 39.4 0.580
5.0 11.5 0.512
2.5 11.3 0.819
7.5 24.3 0.001
0.0 15.4 0.017
5.0 28.6 0.630
7.5 49.9 0.001
7.5 14.1 0.553
9.8 4.8 0.164
0.0 1.0 0.513
2.4 0.6 0.197
0.0 2.8 <0.001
7.5 4.5 0.387
otensin-converting enzyme; ARB, angiotensin receptor blocker; PCI, percutaneous
illator; CRT, cardiac resynchronization therapy.
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Fig. 1. Unadjusted Kaplan–Meier survival curves free from (A) all-cause death, (B) cardiac death, (C) sudden death, and (D) rehospitalization due to heart failure in patients
with  dilated hypertrophic cardiomyopathy (red lines; n = 37) compared with dilated cardiomyopathy (black lines; n = 418).
Table  3
Unadjusted and adjusted hazard ratios for outcomes in HF patients with D-HCM (n = 37) compared with DCM (n = 418).
Outcomes Number (%) HR 95% CI p-Value
D-HCM (n = 37) DCM (n = 418)
All-cause death 11 (29.7%) 60 (14.4%)
Unadjusted 1.969 1.007–3.850 0.043
Adjusted for covariates 1.832 0.775–4.329 0.168
Cardiac death 8 (21.6%) 41 (9.8%)
Unadjusted 2.013 0.902–4.491 0.081
Adjusted for covariates 2.219 0.726–6.777 0.162
Sudden death 3 (8.1%) 11 (2.6%)
Unadjusted 3.181 0.887–11.407 0.061
Adjusted for covariates 0.725 0.058–9.098 0.803
Rehospitalization 16 (43.2%) 133 (31.8%)
Unadjusted 1.542 0.917–2.592 0.102
Adjusted for covariates 1.174 0.578–2.385 0.657
The Cox proportional hazard model was used in the analysis adjusted for the following covariates: age, sex, diabetes mellitus, prior stroke, atrial ﬁbrillation, ventricular
t  fract
P ardio
c
s
t
t
f
H
L
T
c
Dachycardia/ﬁbrillation, heart rate, diastolic blood pressure, left ventricular ejection
atients with DCM were a reference group. D-HCM, dilated phase hypertrophic c
onﬁdence interval.
tudy patients limiting those hospitalized with worsening HF and
he difﬁculty to diagnose D-HCM in the later phase of this disease.
HCM is a heterogenous myocardial disease with a broad spec-
rum of clinical and morphological presentation [20]. LV systolic
unction is supernormal or normal in most patients with HCM.
owever, 3–5% of patients have been shown to progress into
V systolic dysfunction when followed for a long period [9–11].
his type of HCM is usually associated with LV wall thinning and
avity dilatation, resembling the morphologic features of idiopathic
CM and is thus called “the dilated phase of HCM”. However, inion, interventricular septal thickness, and left ventricular posterior wall thickness.
myopathy; DCM, dilated cardiomyopathy; HF, heart failure; HR, hazard ratio; CI,
contrast to DCM, there have been several clinical features reported
in patients with D-HCM; higher incidence of ventricular tachycar-
dia/ﬁbrillation and the resultant poor prognosis [12].
The clinical features of D-HCM in the present study were similar
to those of the previous studies [11,12].  HF patients with D-HCM
were more often male, and more likely to have atrial ﬁbrillation and
sustained ventricular tachycardia/ﬁbrillation (Table 1). A recent
study by Melacini demonstrated that atrial ﬁbrillation was  noted in
64% of patients with HCM complicated by progressive HF and was
identiﬁed as the single most important factor in HF evolution [22].
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trial ﬁbrillation was also related to left atrium size and impaired
V diastolic function in patients with HCM [23]. These ﬁndings
re consistent with previous studies that the combination of atrial
brillation is particularly adverse in patients with HCM [24]. Higher
revalence of atrial ﬁbrillation (Table 1) might be also associated
ith higher rate of prior stroke in patients with D-HCM (Table 2).
The present study demonstrated that D-HCM patients in our
apanese registry received the guideline-recommended medical
reatment for HF with reduced EF including ACE inhibitors, ARBs,
-blockers, and spironolactone (Table 2) [25,26]. The use of these
edications was similar to that for patients with DCM in our study
ohort. An important difference was higher use of amiodarone
nd ICD implantation in the D-HCM group (Table 2), which was
n parallel to high prevalence of sustained ventricular tachycar-
ia/ﬁbrillation (Table 1). ICD implantation should be considered
or patients with D-HCM based on the ﬁnding that sustained or
onsustained ventricular tachycardia is commonly seen and sud-
en cardiac death frequently occurs in these patients [27]. Cardiac
esynchronization therapy is also needed for patients with D-HCM
nd wide QRS because it has been shown to improve the symptoms
nd produce reverse LV remodeling also in this type of patient [28].
n parallel to higher prevalence of atrial ﬁbrillation in patients with
-HCM (Table 1), the use of warfarin was signiﬁcantly higher in
his group (Table 2).
During the long-term follow-up, the mortality rates in patients
ith D-HCM were higher than those with DCM (Fig. 1). These
esults are also consistent with previous studies [11,12]. Harris et al.
emonstrated that the mortality rate was as high as 11% per year
nd sudden death including ICD intervention was  prevalent (34%
f total death) in patients with the end-stage phase of HCM [11].
imilarly, Hamada et al. reported that the 5-year survival rate free
rom all-cause death including cardiac transplantation was lower
n patients with D-HCM than in DCM (45.6% vs. 81.6%; p = 0.0001)
12]. Poor survival might be also due to the progressive myocyte
oss, ﬁbrosis, and the resultant LV wall scarring/thinning in patients
ith D-HCM [29]. Recently, it has been also reported that extracel-
ular matrix protein and proteinase are related to LV remodeling
nd prognosis in patients with HCM [30,31]. Supporting evidence
or this hypothesis is the higher prevalence of ventricular tachy-
ardia in these patients. Although the present study suggested a
igher rate of cardiac death and sudden death in D-HCM, this dif-
erence did not reach statistical signiﬁcance in our studied patients,
hich might be due to relatively high use of treatments known to
e effective for the prevention of sudden cardiac death such as -
lockers and amiodarone as well as ICD (Table 2). Despite the risk
or long-term adverse outcomes, sufﬁcient data are lacking to prove
he effective treatment strategies for HF patients with D-HCM. Cur-
ent HF guideline recommendations include use of ACE inhibitors
nd -blockers, for patients with reduced EF due to either DCM or
-HCM [25,26]. Given the high post-discharge clinical event rate
nd the lack of proven medical therapies for this type of HF, there
s a clear need to establish effective management strategies.
There are several limitations which should be acknowledged
n the present study. First, the present observations included only
ospitalized patients with worsening HF, a population known to
e at increased risk of adverse outcomes including mortality and
ehospitalization. However, by using the criteria regarding their
ymptoms and signs sufﬁciently severe to be hospitalized for HF,
e could enroll patients with reasonably uniform status on admis-
ion. Second, it is difﬁcult to diagnose D-HCM in the late phase of
CM. The diagnosis of HCM was judged by cardiologists that par-
icipated in this study with clinical records and the deﬁnition of
-HCM in this study was previous or current diagnosis of HCM with
educed EF by echocardiography. To accurately diagnose D-HCM,
e need more precise information about the diagnosis of HCM,
ut it is difﬁcult from our national prospective registry database.iology 61 (2013) 65–70 69
Third, data before progressing into D-HCM were not obtained in
the present study and thus we could not include these variables in
the analysis. However, the purpose of this study was  to compare
the clinical characteristics and outcomes of D-HCM with those of
DCM among patients hospitalized due to worsening HF. To clarify
the characteristics and outcomes of D-HCM, we need to establish
a prospective cohort of HCM patients with much longer follow-up.
Fourth, the data were dependent on the accuracy of documenta-
tion and abstraction by individual hospitals and cardiologists that
participated in this study. However, it is not the objective of this
survey to restrict enrollment to the narrowly deﬁned patient pop-
ulation of D-HCM. Fifth, we  did not collect data on family history
because this study intended to analyze HF patients due to various
causes, and was not limited to HCM or DCM. Finally, we did not have
the detailed information regarding the causes of death in our study
patients. Further studies focusing on this crucial issue are clearly
needed in patients with D-HCM vs. DCM.
In conclusion, D-HCM was present in a certain proportion of
hospitalized patients with worsening HF in the large unselected
registry in Japan. Although D-HCM resembles DCM in terms of LV
systolic dysfunction and cavity dilatation, patients with HF and
D-HCM differ signiﬁcantly from those with DCM,  especially with
a higher rate of mortality. Given the high risk of adverse clinical
events and the lack of a sufﬁcient evidence to guide the treat-
ment, clinical trials are needed to identify effective management
strategies for D-HCM.
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